Ocular toxicity of fludarabine: a purine analog
- 1 February 2008
- journal article
- Published by Informa UK Limited in Expert Review of Ophthalmology
- Vol. 3 (1), 97-109
- https://doi.org/10.1586/17469899.3.1.97
Abstract
The purine analogs, fludarabine and cladribine represent an important class of chemotherapy agents used to treat a broad spectrum of lymphoid malignancies. Their toxicity profiles include dose-limiting myelosuppression, immunosuppression, opportunistic infection and severe neurotoxicity. This review summarizes the neurotoxicity of high- and standard-dose fludarabine, focusing on the clinical and pathological manifestations in the eye. The mechanisms of ocular toxicity are probably multifactorial. With increasing clinical use, an awareness of the neurological and ocular vulnerability, particularly to fludarabine, is important owing to the potential for life- and sight-threatening consequences.Keywords
This publication has 39 references indexed in Scilit:
- A Phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disordersLeukemia Research, 2007
- Functional and Genetic Diversity in the Concentrative Nucleoside Transporter, CNT1, in Human PopulationsPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2004
- Oral FludarabineDrugs, 2003
- Cellular and Clinical Pharmacology of FludarabineClinical Pharmacokinetics, 2002
- The bioavailability of oral fludarabine phosphate is unaffected by foodThe Hematology Journal, 2001
- Fludarabine in Resistant or Relapsing B-Cell Chronic Lymphocytic LeukemiaThe Spanish GroupExperienceLeukemia & Lymphoma, 1996
- Fludarabine in Lymphoproliferative Disorders: The Royal Marsden Hospital ExperienceLeukemia & Lymphoma, 1994
- Cellular Pharmacology of Fludarabine Triphosphate in Chronic Lymphocytic Leukemia Cells During Fludarabine TherapyLeukemia & Lymphoma, 1993
- Metabolism of 9-β-D-Arabinosyl-2-fluoroadenine-5′-phosphate by Mice Bearing P388 LeukemiaCancer Drug Delivery, 1983
- Nucleosides of 2-FluoroadenineJournal of Medicinal Chemistry, 1969